Also known as: Trulicity
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist (incretin mimetic) marketed as Trulicity for type 2 diabetes management and cardiovascular risk reduction in eligible adults with type 2 diabetes. It is administered subcutaneously and is prescription-only in major markets. The FDA approved dulaglutide in September 2014.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Orphan drug sales are projected to reach $400 billion by 2032, accounting for over 21% of prescription drug sales. Recent policy changes expanded IRA exemptions for multi-indication orphan drugs and reauthorized pediatric review vouchers. Johnson & Johnson's Darzalex leads orphan drug sales with $31 billion projected revenue.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07677891 |
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE2 |
| NCT07668336 |
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE3 |
| NCT07619495 |
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk |
COMPLETED | |
| NCT07537088 |
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease |
NOT_YET_RECRUITING | PHASE4 |
| NCT07417631 |
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. |
COMPLETED | |
| NCT07417618 |
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) |
COMPLETED | |
| NCT07319286 |
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus |
ENROLLING_BY_INVITATION | PHASE1/PHASE2 |
| NCT07313813 |
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus |
COMPLETED | PHASE1 |
| NCT07282041 |
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis |
RECRUITING | PHASE2/PHASE3 |
| NCT07096063 |
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk |
COMPLETED |
